Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA

Journal of Immunological Methods

Volumn 373, Issue 1-2, 2011, Pages 181-191

  Soman, Gopalan ^a   Yang, Xiaoyi ^a   Jiang, Hengguang ^a   Giardina, Steve ^a   Mitra, Gautam ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Antibody; Cell based enzyme linked immunosorbent assay; Disialoganglioside; Enzyme linked immunono sorbent assay; Potency assay

Indexed keywords

ANTIBODY; CH14.18 PROTEIN; GANGLIOSIDE GD2; GANGLIOSIDE GD2 ANTIBODY; HU 14.18 INTERLEUKIN 2 FUSION PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 2; PROTEIN DERIVATIVE; REAGENT; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; DEVELOPMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MELANOMA CELL; MICROTITER PLATE ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BINDING, COMPETITIVE; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GANGLIOSIDES; HUMANS; INTERLEUKIN-2; MELANOMA; REPRODUCIBILITY OF RESULTS;

EID: 80054842969     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.08.016     Document Type: Article

References (31)

1. Batova A., Kamps A., Gillies S.D., Reisfeld R.A., Yu A.L. The ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin. Cancer Res. 1999, 5:4259.
2. Castel V., Segura V., Cañete A. Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Clin. Transl. Oncol. 2010, 12:788.
3. Gervay J., McReynolds K.D. Utilization of ELISA technology to measure biological activities of carbohydrates relevant in disease status. Curr. Med. Chem. 1999, 6:129.
4. Gillies S.D., Lo K.-M., Weslowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J. Immunol. Meth. 1989, 125:191.
5. Gilman A.L., Ozkaynak M.F., Matthay K.K., Krailo M., Yu A.L., Gan J., Sternberg A., Hank J.A., Seeger R., Reaman G.H., Sondel P.M. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J. Clin. Oncol. 2009, 27:85.
6. King D.M., Albertini M.R., Schalch H., et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J. Clin. Oncol. 2004, 22:4463.
7. Kong Y., Zhang Q., Zhang W., Gee S.J., Li P. Development of a monoclonal antibody-based enzyme immunoassay for the pyrethroid insecticide deltamethrin. J Agric. Food Chem. 2010, 58:8189.
8. Meegan J., Field C., Sidor I., Romano T., Casinghino S., Smith C.R., Kashinsky L., Fair P.A., Bossart G., Wells R., Dunn J.L. Development, validation, and utilization of a competitive enzyme-linked immunosorbent assay for the detection of antibodies against Brucella species in marine mammals. J. Vet. Diagn. Invest. 2010, 22:856.
9. Mueller B.M., Romerdahl C.A., Gillies S.D., Reisfeld R.A. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J. Immunol. 1990, 144:1382.
10. Mujoo K., Cheresh D.A., Yang H.M., Reisfeld R.A. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987, 47:1098.
11. Mujoo K., Kipps T.J., Yang H.M., Cheresh D.A., Wargalla U., Sander D.J., Reisfeld R.A. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 1989, 49:2857.
12. Navid F., Armstrong M., Barfield R.C. Immune therapies for neuroblastoma. Cancer Biol. Ther. 2009, 8:874.
13. Navid F., Santana V.M., Barfield R.C. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr. Cancer Drug Targets 2010, 10:200.
14. Osenga K.L., Hank J.A., Albertini M.R., et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin. Cancer Res. 2006, 12:1750.
15. Ozkaynak M.F., Sondel P.M., Krailo M.D., Gan J., Javorsky B., Reisfeld R.A., Matthay K.K., Reaman G.H., Seeger R.C. Phase I study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group study. J. Clin. Oncol. 2000, 18:4077.
16. Raffaghello L., Marimpietri D., Pagnan G., Pastorino F., Cosimo E., Brignole C., Ponzoni M., Montaldo P.G. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett. 2003, 197:205.
17. Schulz G., Cheresh D.A., Varki N.M., Yu A.L., Staffileno L.K., Reisfeld R.A. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984, 44:5914.
18. Sen G., Chakraborty M., Foon K.A., Reisfeld R.A., Bhattacharya-Chatterjee M. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin. Cancer Res. 1997, 3:1969.
19. Simon T., Hero B., Faldum A., Handgretinger R., Schrappe M., Niethammer D., Berthold F. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1year with metastatic neuroblastoma. J. Clin. Oncol. 2004, 22:3549.
20. Simon T., Hero B., Faldum A., Handgretinger R., Schrappe M., Niethammer D., Berthold F. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin. Pädiatr. 2005, 217:147.
21. Simon T., Hero B., Faldum A., Handgretinger R., Schrappe M., Klingebiel T., Berthold F. Long-term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011, 11:21.
22. Sondel P.M., Hank J.A. Combination therapy with interleukin-2 and antitumor monoclonal antibodies. Cancer J. Sci. Am. 1997, 3(Suppl 1):S121.
23. Svennerholm L., Boström K., Fredman P., Jungbjer B., Lekman A., Månsson J.-E., Rynmark B.-M. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim. Biophys. Acta 1994, 1214:115.
24. Waerner T., Girsch T., Varga S., Huang L., Gornikiewicz A., Loeber G. A receptor-binding-based bioassay to determine the potency of a plasmid biopharmaceutical encoding VEGF-C. Anal. Bioanal. Chem. 2007, 389:2109.
25. Yamane B.H., Hank J.A., Albertini M.R., Sondel P.M. The development of antibody-based immunotherapy with (EMD-273063) Hu14.18IL-2 in melanoma and neuroblastoma. Expert Opin. Investig. Drugs 2009, 18:991.
26. Yang R.K., Sondel P.M. Anti-GD2 Strategy in the treatment of neuroblastoma. Drugs Future 2010, 35:665.
27. Yang X.Y., Jiang H., Hartmann W.K., Mitra G., Soman G. Development of a quantitative antigen-specific, cell-based ELISA for the 7G7/B6 monoclonal antibody directed toward IL-2Ra. J. Immunol. Meth. 2003, 277:87.
28. Yang X.Y., Chen E., Hartmann W.K., Mitra G., Hecht T., Soman G. Development of a quantitative antigen-specific, cell-based ELISA for humanized anti-IL-2/Il-15 receptor b antibody (HuMikb1) and correlation with functional activity using an antigen-transfected murine cell line. J. Immunol. Meth. 2006, 311:71.
29. Yoshida S., Fukumoto S., Kawaguchi H., Sato S., Ueda R., Furukawa K. Ganglioside GD2 in small-cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res. 2001, 61:4244.
30. Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S.G., Chen H.X., Smith M., Anderson B., Villablanca J.G., Matthay K.K., Shimada H., Grupp S.A., Seeger R., Reynolds C.P., Buxton A., Reisfeld R.A., Gillies S.D., Cohn S.L., Maris J.M., Sondel P.M. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J. Med. 2010, 363:1324.
31. Zhang S., Cordon-Cardo C., Zhang H.S., Reuter V.E., Adluri S., Hamilton W.B., Lloyd K.O., Livingston P.O. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 1997, 73:42.